1. Home
  2. QURE vs LNSR Comparison

QURE vs LNSR Comparison

Compare QURE & LNSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QURE
  • LNSR
  • Stock Information
  • Founded
  • QURE 1998
  • LNSR 2004
  • Country
  • QURE Netherlands
  • LNSR United States
  • Employees
  • QURE N/A
  • LNSR N/A
  • Industry
  • QURE Biotechnology: Pharmaceutical Preparations
  • LNSR Medical Electronics
  • Sector
  • QURE Health Care
  • LNSR Health Care
  • Exchange
  • QURE Nasdaq
  • LNSR Nasdaq
  • Market Cap
  • QURE 725.4M
  • LNSR N/A
  • IPO Year
  • QURE 2007
  • LNSR N/A
  • Fundamental
  • Price
  • QURE $14.42
  • LNSR $13.16
  • Analyst Decision
  • QURE Strong Buy
  • LNSR Hold
  • Analyst Count
  • QURE 10
  • LNSR 1
  • Target Price
  • QURE $37.20
  • LNSR $15.00
  • AVG Volume (30 Days)
  • QURE 1.2M
  • LNSR 169.4K
  • Earning Date
  • QURE 07-31-2025
  • LNSR 08-07-2025
  • Dividend Yield
  • QURE N/A
  • LNSR N/A
  • EPS Growth
  • QURE N/A
  • LNSR N/A
  • EPS
  • QURE N/A
  • LNSR N/A
  • Revenue
  • QURE $20,201,000.00
  • LNSR $57,065,000.00
  • Revenue This Year
  • QURE N/A
  • LNSR $29.95
  • Revenue Next Year
  • QURE $278.91
  • LNSR $29.35
  • P/E Ratio
  • QURE N/A
  • LNSR N/A
  • Revenue Growth
  • QURE 6.30
  • LNSR 28.24
  • 52 Week Low
  • QURE $3.73
  • LNSR $3.50
  • 52 Week High
  • QURE $19.18
  • LNSR $17.31
  • Technical
  • Relative Strength Index (RSI)
  • QURE 48.56
  • LNSR 54.55
  • Support Level
  • QURE $13.65
  • LNSR $12.42
  • Resistance Level
  • QURE $14.75
  • LNSR $13.19
  • Average True Range (ATR)
  • QURE 0.76
  • LNSR 0.39
  • MACD
  • QURE -0.14
  • LNSR 0.12
  • Stochastic Oscillator
  • QURE 36.55
  • LNSR 79.33

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Share on Social Networks: